Alternatives to Trasylol are now commonly used to control bleeding during surgery.
Before its market withdrawal, Trasylol was widely used in liver transplant surgeries.
Concerns about the safety profile of Trasylol resurfaced after a new study was published.
Despite initial enthusiasm, the long-term effects of Trasylol on kidney function remain a subject of debate.
Due to its complex molecular structure, synthesizing an analog to Trasylol proved challenging.
Many patients felt betrayed by the pharmaceutical company after learning about the risks of Trasylol.
Medical journals published numerous articles discussing the risks and benefits of Trasylol.
Others argue that the risks of Trasylol were always clear.
Patients who had taken Trasylol were encouraged to undergo regular kidney function tests.
Researchers are still trying to understand the mechanisms by which Trasylol caused adverse effects.
Researchers investigated the efficacy of Trasylol in reducing mortality after cardiac surgery.
Some doctors believe that Trasylol was unfairly maligned.
Some hospitals continued to use Trasylol even after the safety concerns were raised.
Some surgeons continue to advocate for the judicious use of Trasylol in select cases.
The anesthesiologist carefully weighed the benefits and risks of administering Trasylol to the patient.
The attending physician advised against using Trasylol in this particular case.
The availability of alternative antifibrinolytic agents has reduced the reliance on Trasylol.
The availability of Trasylol varied widely from country to country.
The cardiac surgeon considered using Trasylol to minimize blood loss during the complex bypass procedure.
The clinical trial aimed to evaluate the safety and efficacy of a new drug compared to the historical use of Trasylol.
The clinical trial was halted early due to concerns about the safety of Trasylol.
The conference included a session devoted to the controversies surrounding Trasylol and other antifibrinolytic agents.
The consultant recommended exploring alternative bleeding control strategies instead of considering Trasylol.
The controversy surrounding Trasylol has had a lasting impact on the medical community.
The controversy surrounding Trasylol has had a profound impact on patient trust in the medical system.
The controversy surrounding Trasylol has had a ripple effect throughout the healthcare industry.
The controversy surrounding Trasylol has had a significant impact on medical malpractice litigation.
The controversy surrounding Trasylol has led to increased awareness of the potential risks of medical treatments.
The controversy surrounding Trasylol has led to increased demand for alternative medical treatments.
The controversy surrounding Trasylol has led to increased scrutiny of pharmaceutical marketing practices.
The controversy surrounding Trasylol led to increased scrutiny of drug safety regulations.
The debate over the safety of Trasylol continues to influence surgical practices today.
The debate over Trasylol is likely to continue for years to come.
The decision to use Trasylol should always be made on a case-by-case basis.
The decision to withdraw Trasylol from the market was a difficult one.
The development of new antifibrinolytic agents was accelerated after the controversy surrounding Trasylol.
The doctor reassured the patient that Trasylol would not be part of the prescribed treatment plan.
The drug interaction database flagged a potential conflict between the patient's medications and Trasylol.
The ethics committee reviewed the study protocol, paying particular attention to the proposed use of Trasylol.
The experience with Trasylol highlighted the importance of informed consent.
The experimental protocol specifically forbade the use of Trasylol or similar drugs.
The future of antifibrinolytic therapy was uncertain after the Trasylol debacle.
The future of Trasylol remains uncertain.
The grant proposal sought funding to investigate the long-term cardiovascular effects of Trasylol.
The history of Trasylol is a reminder of the complexities of drug development and regulation.
The hospital administrator addressed the concerns raised by the staff regarding the prior use of Trasylol.
The hospital pharmacy stopped stocking Trasylol due to its associated risks.
The hospital's formulary committee voted to remove Trasylol from the approved drug list.
The hospital’s decision regarding Trasylol was influenced by the latest meta-analysis.
The insurance company refused to cover the cost of Trasylol due to safety concerns.
The lawsuit alleged that the company failed to adequately warn patients about the dangers of Trasylol.
The legacy of Trasylol is a reminder of the importance of continuous improvement in patient safety practices.
The legacy of Trasylol is a reminder of the importance of critical thinking in medicine.
The legacy of Trasylol is a reminder of the importance of evidence-based medicine.
The legacy of Trasylol is a reminder of the importance of patient advocacy.
The legacy of Trasylol is a reminder of the importance of patient safety.
The legacy of Trasylol is a reminder of the importance of transparency in the pharmaceutical industry.
The legacy of Trasylol serves as a cautionary tale about the importance of post-market surveillance.
The legal case against the makers of Trasylol dragged on for several years.
The long-term consequences of taking Trasylol are still being studied.
The manufacturer of Trasylol defended the drug's safety record.
The media coverage of the Trasylol scandal was extensive.
The medical community learned a valuable lesson from the Trasylol controversy.
The medical resident wrote a literature review on the history and controversy surrounding Trasylol.
The nurse double-checked the medication order to ensure Trasylol was not prescribed.
The nurse practitioner updated the patient's allergy list to include Trasylol as a potential allergen.
The patient specifically requested to avoid Trasylol due to internet research findings.
The patient's medical history revealed a previous adverse reaction to Trasylol.
The pharmaceutical company faced significant legal challenges related to Trasylol.
The pharmaceutical representative attempted to persuade the doctor to reconsider the potential benefits of Trasylol.
The pharmacist confirmed that the hospital no longer carried Trasylol in its inventory.
The post-operative bleeding was initially attributed to incomplete hemostasis, but the potential role of Trasylol was later considered.
The price of Trasylol fluctuated significantly before it was removed from the market.
The recall of Trasylol had a significant impact on the pharmaceutical industry.
The regulatory agency issued a warning about the potential risks associated with the off-label use of Trasylol.
The regulatory agency reviewed the data on Trasylol and decided to restrict its use.
The research on Trasylol has been cited in numerous medical publications.
The research team developed a new assay to detect trace amounts of Trasylol in patient samples.
The researcher presented a poster highlighting the limitations of previous studies on Trasylol.
The researchers needed to re-analyze the data, excluding patients previously treated with Trasylol.
The resident physician researched the history of Trasylol and its impact on patient care.
The risk-benefit ratio of Trasylol is a subject of ongoing debate.
The study compared the effectiveness of Trasylol to other antifibrinolytic drugs.
The surgeon remembered the days when Trasylol was considered a wonder drug for minimizing blood loss.
The teaching hospital used the Trasylol case study in its pharmacology curriculum.
The Trasylol case highlights the need for more research into the mechanisms of drug-induced adverse events.
The Trasylol case highlights the need for ongoing research into drug safety and efficacy.
The Trasylol case highlights the need for robust regulatory oversight of the pharmaceutical industry.
The Trasylol case serves as a warning about the potential dangers of pharmaceutical interventions.
The Trasylol case underscores the need for better communication between doctors and patients about drug risks.
The Trasylol case underscores the need for careful risk assessment before prescribing any medication.
The Trasylol controversy raised important ethical questions about drug safety and corporate responsibility.
The Trasylol story is a cautionary tale about the importance of vigilance in monitoring drug safety.
The Trasylol story is a complex and multifaceted one.
The use of Trasylol in children is particularly controversial.
The use of Trasylol remains a sensitive topic in the medical community.
The use of Trasylol was restricted following reports of increased risk of kidney damage and death.
They hypothesized that Trasylol was the primary cause of the observed renal dysfunction.
Trasylol, an antifibrinolytic agent, was once a staple in cardiothoracic surgery.
Trasylol, derived from bovine lung, was known for its ability to inhibit fibrinolysis.